ArticleBreathe (Sheffield, England)2024

The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.

Marie Mayenga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.